
If you haven’t been watching what Lilly and Novo Nordisk are doing right now, buckle up. They’ve been firing off cease-and-desist letters to compounding pharmacies over tirzepatide and semaglutide for months, claiming IP infringement on Mounjaro and Ozempic. But now they’ve crossed into…




